TD Cowen analyst Phil Nadeau has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Phil Nadeau has given his Buy rating due to a combination of factors, including ELVN-001’s strong early clinical performance in chronic myeloid leukemia and a clear path toward pivotal development. The Phase 1a/b data show competitive rates of major molecular responses and deep molecular responses across multiple dose levels, supporting confidence that the drug can be an effective treatment option.
Nadeau also highlights management’s plans to present updated data at EHA mid-year and to align with the FDA on dose and design for the ENABLE-2 Phase 3 trial, targeted to start in the second half of 2026. With approximately $452 million in cash on hand expected to fund operations into the first half of 2029, Enliven’s balance sheet is viewed as sufficient to reach key value-creating milestones, reinforcing the Buy recommendation on ELVN.
According to TipRanks, Nadeau is a 5-star analyst with an average return of 11.8% and a 50.63% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Biogen, MoonLake Immunotherapeutics, and Rhythm Pharmaceuticals.